India Biotech releases final data of Phase-3 clinical trial, vaccine 65% effective on Delta variant; 93% effective even in severe cases

78% effective:  



Covexin is effective on critically ill patients and patients of the Delta variant.

Covexin has also been found to be 65.2% effective against the Delta variant



Indigenous vaccine maker Bharat Biotech has completed the trial of the third and final phase of Covaxin Vaccine, with the company officially announcing the results of the third phase. It was said that covexin has been found to be effective on critically ill patients and patients of the Delta variant.

Covexin has also been found to be 65.2% effective against the worldwide threat Delta variant, while Covexin is 93.4% effective in preventing serious infections. Based on the results of the third phase, Bharat Biotech said that covexin was found to be 77.8% effective overall against Corona.



Delta is a variant effective
when the world has found the vaccine to be effective against the spread of dangerous delta variant 65.2%, while 93.4% koveksina found to be effective to prevent serious infection. Has been shown to be 63.6% effective in patients with asymptomatic coronary heart disease.

Covexin has been found to be 65.2% effective against the Delta variant.

Efficacy of covexin 77.8%
A third phase trial of covexin found an overall efficacy of 77.8%, while an overall efficacy of 93.4% was found on severe coronavirus infection.

Covexin was reported to be 67.8% effective on people over 60 and 79.4% on people under 60, although serious side effects were also observed in about 99 volunteers during the third phase trial.

Covexin is 93.4% effective in preventing serious infections.

Find out how effective covexin is in any case-

Asymptomatic case: 63% effective.
Delta variant: 65% effective.

ALSO READ 

Viral Video: 10-year-old video of Hardik Pandya batting hard, bowlers' sweat released

Mild, moderate and severe cases: 78% effective.
Cases of severe corona: 93% effective; Let me tell you that the company has conducted this trial on 130 confirmed cases of Corona.



The data was approved by the SEC. The
company had given the data of the trial to the Drug Controller General of India (DCGI) a few days back. An important meeting of the Subject Expert Committee (SCE) was then held and the data for the third phase of the vaccine trial were leaked.

also read 

Assam Rifles Recruitment 2021-22|Apply Online 131 GD Constable Vacancy

WHO approves EOI
Earlier, Bharat Biotech's Expression of Interest (EOI) was accepted by WHO. The company submitted an EOI on April 19 after Kovexin was approved.



What is the significance of WHO's emergency use approval?


ALSO READ 

Uttam Dairy Ahmedabad Recruitment For Driver Posts 2021

The WHO's Emergency Use Listings examines the safety and effectiveness of health products in public health emergencies such as epidemics. The WHO approved the emergency use of the Pfizer vaccine on 31 December 2020, the Oxford-AstraZeneca vaccine on 15 February 2021 and the Johnson & Johnson vaccine on 12 March.

Read in Gujarati news 

According to the WHO, medicines, vaccines and diagnostic tools need to be developed and approved as soon as possible in view of the state of emergency. It also meets safety, efficiency and quality standards. This assessment ensures the usefulness of these products for a wide range of people during an epidemic.